One year on from expanding the Chronic Kidney Disease (CKD) Management Pathway across all boroughs of NCL, what insights have been gained? Which individuals with CKD benefit from SGLT-2 inhibitors (flozins)? What should you do if someone's potassium rises on an ACEi or ARB? What is Finerenone and what is its role in the management of diabetic kidney disease?

Join the panel of experts to learn about key updates to the NCL CKD Pathway in 2025, which reflect new guidance for these medications that will increase the number of people who can benefit from the reduction in cardiovascular disease mortality, and progression to dialysis. The webinar will conclude with a Q&A session, providing an opportunity to ask questions directly to the experts.

Panel members:

• Sarah Milne, Kidney Nurse Consultant, CKD Lead RFL and co-chair NCL CKD Steering Group
• Sarah Morgan, GP CKD lead for NCL, and co-chair NCL CKD Steering Group
• Dr Mark Jesky, Consultant Nephrologist and Clinical Lead for Renal Services
• Professor David Wheeler, Professor of Kidney Medicine and Honorary Consultant Nephrologist
• Sinead Burke, Lead CKD Dietitian 

For further information, contact Sinead Burke, Lead CKD Dietitian rf.communityckdservice@nhs.net